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Abstract
Post concussion syndrome (PCS) is a set of symptoms succeeding in 25 % of mild traumatic brain injury (mTBI)
patients. Hyperbaric oxygen therapy (HBOT) has been demonstrated as an effective method for treating acute and
severe TBI, but its efficacy in PCS remains controversial. In this editorial, we reviewed the clinical studies of HBOT in
PCS, summarized the limitations of these studies, and discussed the limitations: inappropriate Sham group using
room air at 1.2 or 1.3 ATA; delayed HBO administration; subjective assessment methods; time point for outcome
assessment and small sample size. We hope that our concerns will be helpful for future clinical studies of HBO
therapy in TBI or other neurological disorders.
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Commentary
Hyperbaric oxygen therapy for Post concussion
Symptoms: issues may affect the results
Post concussion syndrome (PCS) is a set of symptoms
succeeding in 25 % of mild traumatic brain injury (mTBI)
patients [1]. The symptoms of PCS include headache, dizzi-
ness, neuropsychiatric symptoms, and cognitive impair-
ments, and may continue for weeks, months, or a year or
more. Hyperbaric oxygen therapy (HBOT) is an effective
method for treating acute and severe TBI [2], however,
effects of HBOT in the treatment of PCS has not been well
established. By our current research in Pubmed, using key
words “hyperbaric oxygen and post concussion syndrome”,
we were able to identified seven articles to this topics.
HBOT was effective in three [3–5] but failed in four studies
[6–9]. The studies from Boussi-Gross R et al [3] and Harch
PG et al [4, 5] showed HBOT (1.5 atmospheres absolute
[ATA], 60 min once or twice daily for 40 sessions) signifi-
cantly improved symptoms, cognitive abilities, and quality
of life, with concomitant improvements in single photon
emission computed tomography (SPECT) imaging. In the
three positive studies, there were no control groups and
they compared the data pre- and post-HBOT to get the
conclusion. However, the results from the studies of David
X. Cifu et al [6, 7], R. Scott Miller et al [8] and George Wolf
et al [9] failed to prove the therapeutic effects of hyperbaric
oxygen (HBO) in PCS after mild TBI. In these four pro-
spective, randomized studies, the subjects were U.S. mili-
tary service members, and received 30 to 40 sessions of
either a sham or HBO (1.5–2.4 ATA, 60 min once daily) in
the treatment of PCS after mild TBI; and the outcome was
primarily assessed by the Rivermead Post-Concussion
Symptoms Questionnaire (RPQ). In Dr. Miller’s study, the
authors concluded that HBO is ineffective for the treatment
of PCS, but the ritual of the intervention does. It has been
shown through these various studies that the effects of
HBOT in PCS are controversial. We believe that there are
numerous inherent limitations in these studies, which
contributed significantly to misinterpretation of the HBO
effects. We want to discuss these limitations, and hope that
our concerns will be helpful for future clinical studies of
HBOT in TBI or other neurological disorders.
The usage of a correct placebo is a dilemma, which has
been controversially debated in the field of HBO therapy.
In Dr. Miller’s and Dr. Wolf ’s studies, the sham group
received a treatment with a pressurized room air at 1.2
ATA or 1.3 ATA [8, 9]. The authors have mentioned that
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the remarkable strengths of their studies are well-designed
control groups. This allowed the participants to sense pres-
sure increases with minimal biological function. Authors
believed the improvement in HBO and Sham groups is due
to the placebo effects from the intensive rituals of the
repetitive chamber procedures, rather than oxygen effects.
Of course, the placebo effects cannot be ruled out entirely;
however, there are other arguments speaking against such
interpretation of the observed results. Can room air at 1.2
ATA really serve as a proper sham-control due to it being
“logically implausible to have a beneficial effect”? The
“sham” control group was exposed to 1.2 ATA of room air,
which is a 20 % increase in pressure and, that, theoretically,
should increase plasma oxygen for about 30 % compared to
normal pressure. Some case reports clearly demonstrate
biological effects of even insignificant increases of air pres-
sure in different tissues, including effects on the brain [10].
Similarly, randomized, controlled clinical trials have shown
that room air at 1.3/1.2 ATA leads to meaningful improve-
ments of neurological functions [9, 10]. Previous studies
demonstrated that treatment with medical air under mild
pressure could have a beneficial effect. Interesting enough,
Miller et al. are aware of this finding and they have men-
tioned it in the “discussion” section. Both Miller and Wolf
failed, however, to provide the result of blood plasma
oxygen measurement of the sham group, one of the most
imperative physiological parameter of this study, and failed
to show the dose response of HBO in the patients. In the
other three positive studies from Boussi-Gross R et al [3]
and Harch PG et al [4, 5], they used self controlled case-
series design method to overcome the placebo issue by
comparing the results pre- and post-HBOT.
The optimal time for HBO administration is one of the
crucial facts that determine its efficacy in TBI and other
neurological diseases. The neuroprotective effects of HBO
have all been achieved when intervention was administered
during the acute phase, within hours after TBI [11–16].
The prolonged therapeutic time window of HBO was fur-
ther investigated in animal models of TBI. Yang et al.
showed HBO treatment decreased apoptosis and improved
cognitive ability when it was given 6 hours after TBI in rats,
while failed to work when given 60 days after TBI [16].
Wang and colleagues have demonstrated that multiple ses-
sions of HBO (3 ATA hourly for 3 or 5 days) extended the
time window of HBO compared to a single session up to
48 hours post-TBI and significantly reduced overall neuro-
logical deficit scores and neuronal apoptosis [17]. The data
of these pre-clinic and clinic studies indicated that HBO is
beneficial when it is applied in the early stage. Most PCS
patients were treated more than one year after the onset of
the most recent TBI. It would be more logical to start HBO
treatments within a therapeutic time window established in
preclinical study. Whether earlier HBO therapy affords
clear benefits remains to be determined.
Objective and precise assessment methods are another
challenge in the evaluation of the efficacy of HBO ther-
apy in PCS patients. In most studies, the outcome was
evaluated by the Rivermead Post-Concussion Symptoms
Questionnaire (RPQ), Neurobehavioral Symptom Inven-
tory and Automated Neuropsychological Assessment
Metrics. All assessments are well established, however,
they are all subjective performance evaluations. It is well
known that RPQ displays several flaws in its implemen-
tation and in its ability to accurately reflect test-taker
experience [18]. Interpretation and accuracy of the RPQ
can vary widely due to self-administration and the various
confounding variables involved, because it is sensitive to
subjective patient memory, social desirability, stress, and
other covariates such as personality factors and willingness
to reveal problems, as are the two other methods. The
authors relied totally on the self-administration assess-
ments which is a weakness of these failed studies. Add-
itionally, in many studies, participants in HBO and sham
groups were given different medications on board and
undergoing nonpharmacological interventions for post-
traumatic stress disorder (PSD) treatment. These profes-
sional psychiatric treatments for PSD may contribute to,
or account for, the elevated RPQ and mask the efficacy of
HBO. The correlation between medication status and
scores on any of these measurements should be studied in
the future studies. In the three positive studies, the reso-
lution of symptoms and signs of TBI/PCS were reflected
in global and focal improvements in brain blood flow ana-
lyzed by SPECT. Even though SPECT imaging or electro-
physiological measurements may not sensitive enough to
detect abnormal in some patients with PCS, it is an object-
ive assessment methods that can provide authentic evi-
dences for HBO or sham interventions and allow a greater
refinement of HBO application in mTBI.
Forth, the time point for outcome assessment may be
one of the factors that affect the effects of HBOT. In this
article, all the subjects of these seven studies were mild
TBI patients with prolonged PCS at late chronic stage
(three month to three years after the first TBI), and
post-exposure assessments of HBOT were performed at
3 days [5], 1 week [4], 1 month [8], 6 weeks [9], 2 month
[3], and 3 month [6, 7] after the last chamber exposure.
The different time points for outcome assessments may
be another contributor to the varied results. In addition,
restoration of neurological deficits is a slow process, and
TBI patients at the chronic late stage may need more
time to demonstrate the effects of HBOT. Evaluation of
the outcome 6 or 12 month after HBOT is much more
preferable.
At last, the small sample size limits the power of these
studies. In the three positive studies, the sample number is
24 in crossover group and 32 in HBOT group [3], 16 [4]
and 1 [5] in HBOTgroup respectively. In other four studies,
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in Cifu’s study, the eligible participants in Sham, 1.5 ATA
HBO and 2.0 ATA HBO groups were 21, 21, and 19. In Dr.
Miller’s study, the numbers of patients Intent-to-Treat in
HBO and Sham groups are 23, 21 respectively; and the ac-
tual number in HBO and Sham groups finishing the whole
project are 11 and 13 respectively. The inadequacy of sam-
ple size might bias the results and lead to an incorrect
conclusion.
HBOT has showed great potential in neuroprotection
and neurogenesis, and the inefficacy of HBOT in PCS in
these four clinic studies demands a cautious interpret-
ation. The incorrect sham group, delayed treatment time,
inappropriate outcome measurements, time point for
outcome assessment and limited number of patients could
contribute to misinterpretation of results and prevent a
positive recommendation of HBO in PCS. We hope these
key factors can be considered in the future clinical studies
of HBO in mTBI and other neurological diseases.
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